In this issue of Blood , Huber et al(1) present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL).
机构:
CNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, ItalyCNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, Italy
De Luca, A
Caraveo, PA
论文数: 0引用数: 0
h-index: 0
机构:
CNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, ItalyCNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, Italy
Caraveo, PA
Mereghetti, S
论文数: 0引用数: 0
h-index: 0
机构:
CNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, ItalyCNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, Italy
Mereghetti, S
Negroni, M
论文数: 0引用数: 0
h-index: 0
机构:
CNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, ItalyCNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, Italy
Negroni, M
Bignami, GF
论文数: 0引用数: 0
h-index: 0
机构:
CNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, ItalyCNR, Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, Italy